Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

VIPoma secondary prevention

Introduction

Overview

Overview

Effective measures for the secondary prevention of VIPoma include history and physical examination, serum VIP levels and indicated markers, and multi-phasic CT scan or MRI.

Secondary Prevention

Secondary Prevention

Effective measures for the secondary prevention of VIPoma include:[1][2][3]

Note: These follow-up should be done every 3 to 12 months up to one year post resection and every 6 to 12 months thereafter.

References

References

  1. ↑ Kulke, Matthew H.; Benson, Al B.; Bergsland, Emily; Berlin, Jordan D.; Blaszkowsky, Lawrence S.; Choti, Michael A.; Clark, Orlo H.; Doherty, Gerard M.; Eason, James; Emerson, Lyska; Engstrom, Paul F.; Goldner, Whitney S.; Heslin, Martin J.; Kandeel, Fouad; Kunz, Pamela L.; Kuvshinoff, Boris W.; Moley, Jeffrey F.; Pillarisetty, Venu G.; Saltz, Leonard; Schteingart, David E.; Shah, Manisha H.; Shibata, Stephen; Strosberg, Jonathan R.; Vauthey, Jean-Nicolas; White, Rebekah; Yao, James C.; Freedman-Cass, Deborah A.; Dwyer, Mary A. (2012). “Neuroendocrine Tumors”. Journal of the National Comprehensive Cancer Network. 10 (6): 724–764. doi:10.6004/jnccn.2012.0075. ISSN 1540-1405.
  2. ↑ Kunz, Pamela L.; Reidy-Lagunes, Diane; Anthony, Lowell B.; Bertino, Erin M.; Brendtro, Kari; Chan, Jennifer A.; Chen, Herbert; Jensen, Robert T.; Kim, Michelle Kang; Klimstra, David S.; Kulke, Matthew H.; Liu, Eric H.; Metz, David C.; Phan, Alexandria T.; Sippel, Rebecca S.; Strosberg, Jonathan R.; Yao, James C. (2013). “Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors”. Pancreas. 42 (4): 557–577. doi:10.1097/MPA.0b013e31828e34a4. ISSN 0885-3177.
  3. ↑ Bourcier, Matthew E.; Vinik, Aaron I. (2013). “Sunitinib for the Treatment of Metastatic Paraganglioma and Vasoactive Intestinal Polypeptide-Producing Tumor (VIPoma)”. Pancreas. 42 (2): 348–352. doi:10.1097/MPA.0b013e31825c53fa. ISSN 0885-3177.

Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]